Roche Expands Digital Pathology Strategy with Acquisition of AI Diagnostics Company PathAI

Roche Expands Digital Pathology Strategy with Acquisition of AI Diagnostics Company PathAI

(IN BRIEF) Roche has agreed to acquire PathAI to strengthen its digital pathology and AI-powered diagnostics capabilities. The deal builds on an existing partnership between the companies focused on AI-enabled companion diagnostics and pathology solutions. Roche said the acquisition will integrate PathAI’s AISight image management system and AI analysis tools into its diagnostics portfolio, helping improve laboratory efficiency, cancer diagnosis and personalised treatment development. The combination is also expected to enhance biomarker discovery, clinical trial support and precision medicine research for biopharma customers. Roche will pay USD 750 million upfront with potential milestone payments of up to USD 300 million, subject to regulatory approvals and closing conditions.

(PRESS RELEASE) BASEL, 7-May-2026 — /EuropaWire/ — Roche has entered into a definitive merger agreement to acquire PathAI in a move designed to strengthen its digital pathology and AI-driven diagnostics capabilities while accelerating the development of personalised healthcare solutions.

The acquisition expands a partnership between the two companies that began in 2021 and was broadened in 2024 to include the development of AI-enabled companion diagnostic algorithms. Upon completion of the transaction, PathAI will become part of Roche’s Diagnostics division.

Roche said the acquisition will enhance its position within the rapidly growing field of digital pathology, where artificial intelligence and automation technologies are increasingly being integrated into pathology laboratories to improve workflow efficiency, diagnostic accuracy and clinical decision-making.

Digital pathology enables physical tissue samples mounted on slides to be converted into high-resolution digital images that can then be analysed using AI-powered tools. These technologies are designed to support pathologists in diagnosing diseases such as cancer more efficiently while helping physicians make faster and more targeted treatment decisions.

Matt Sause said digital pathology has the potential to significantly improve precision cancer diagnosis and support more personalised treatment strategies for patients. He added that integrating PathAI’s technology with Roche’s oncology diagnostics portfolio could help provide physicians with better clinical insights and potentially improve patient outcomes worldwide.

The transaction will bring PathAI’s AISight image management system into Roche’s digital pathology portfolio. The platform combines image management, workflow tools and advanced AI analysis capabilities within a unified software environment designed for pathology laboratories. Roche said it intends to expand the deployment of the system globally.

The companies also highlighted the strategic importance of combining Roche’s strong position in companion diagnostics with PathAI’s expertise in AI-driven pathology solutions, translational research and clinical trial support. According to Roche, the integration could accelerate biomarker discovery, identify potential drug targets and support development of new diagnostic tools for pharmaceutical research and precision medicine.

Andy Beck described the agreement as a major milestone for PathAI and said Roche’s global infrastructure and diagnostics expertise would allow the company’s AI-powered pathology technologies to reach patients at significantly greater scale and speed.

Under the terms of the agreement, Roche will pay an upfront purchase price of USD 750 million with additional milestone payments of up to USD 300 million tied to future performance targets and development milestones.

The transaction remains subject to customary closing conditions, including antitrust and regulatory approvals, and is currently expected to close during the second half of 2026.

The acquisition reflects growing investment activity within the healthcare and diagnostics sectors as pharmaceutical and medical technology companies increasingly integrate artificial intelligence into clinical workflows, precision medicine and drug development operations.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Media Contacts:

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America